efgartigimod
Sponsor Argenx SE · listed as ARGX
efgartigimod is a drug asset sponsored by Argenx SE, listed as ARGX. CSA tracks 1 forward catalyst for it — the nearest is a readout expected Mar 2027 (month precision, medium confidence), tied to trial NCT04833894. That trial is in Phase 2/3 and currently recruiting, studying Generalized Myasthenia Gravis. It appears across 3 tracked trials in the CSA sample.
Next catalyst
Trial & sponsor
Trials for efgartigimod in the CSA sample
| Trial | Phase | Status | Primary completion | Role | Lead sponsor | Condition(s) |
|---|---|---|---|---|---|---|
| NCT06298552 | Phase 3 | Active, not recruiting | 2025-06-30 | Experimental | argenx | Generalized Myasthenia Gravis; gMG; Myasthenia Gravis, Generalized; Myasthenia Gravis |
| NCT04833894 catalyst | Phase 2/3 | Recruiting | 2027-03 | Experimental | argenx | Generalized Myasthenia Gravis |
| NCT07217587 | Phase 3 | Recruiting | 2027-09-28 | Active comparator | Janssen Research & Development, LLC | Myasthenia Gravis |
Each trial links to its ClinicalTrials.gov record; primary completion dates are as registered there.
Data, not investment advice. CSA is information, not a recommendation to buy, sell or hold any security. Estimated catalyst dates routinely slip and are graded by confidence — verify against the source link before acting.
This page is one record from the free CSA sample. The full snapshot covers active, industry-sponsored Phase 3 trials in cardiometabolic, oncology and immunology. Every forward catalyst carries its date, confidence grade and source link, and is linked to its sponsor's ticker when the sponsor is a listed company.
Get the full dataset — $499 → More ARGX catalysts